Can we Boost Emicizumab Without Increasing Thrombosis Risk? – RPTH Journal
RPTH Journal shared a post on LinkedIn:
”Can we boost emicizumab without increasing thrombosis risk?
Emicizumab transformed hemophilia A care.
But breakthrough bleeding still happens, and treatment options remain imperfect.
A new RPTH study explores a provocative idea:
What if adding low-dose FIX plus FX together could safely enhance emicizumab-driven coagulation?
Here’s the key signal:
Combined FIX/FX supplementation restored coagulation potential to near-normal levels in vitro, in patient samples, and in hemophilia A mice.
Why this is biologically plausible:
- Emicizumab works by bridging FIXa and FX
- More FIX + FX to more ternary complex formation
- ~2× increase in FIX–emicizumab–FX complexes predicted
- Faster clot formation and reduced bleeding in vivo
- Thrombotic markers did not increase in animal models
Translation:
Rather than pushing bypassing agents harder, we may be able to optimize the emicizumab pathway itself.
Big questions for clinicians and researchers:
- Could FIX+FX become an alternative to rFVIIa for breakthrough bleeds?
- Could this strategy reduce treatment burden and dosing frequency?
- How do we balance enhanced hemostasis with real-world thrombosis risk?”
Title: Augmented emicizumab-driven coagulation potential in hemophilia A state by in vitro and in vivo supplementation of combined factors IX and X
Authors: Mitsumasa Osuna, Yuto Nakajima, Eisuke Takami, Hirotoshi Nakano, Keiji Nogami
Find the Full Article on RPTH.”
Stay updated with Hemostasis Today.
-
Jul 6, 2026, 19:25Ambreen Kashif: Highlighting the Impact of Temporary Donor Deferrals on Donor Retention
-
Jul 6, 2026, 19:23Rob Mac Sweeney: Anticoagulation Strategies for Cardiopulmonary Bypass in Heparin-Induced Thrombocytopenia
-
Jul 6, 2026, 19:22Nthabiseng Bapela: Interpreting INR in Patients on Warfarin – A Practical Clinical Framework
-
Jul 6, 2026, 19:20Hamza Mohamed: Key Highlights from the 2026 AHA/ACC Multisociety Guideline on Acute PE
-
Jul 6, 2026, 18:58Mostafa Faisal: High PNH Type II Neutrophil Proportions Are Associated With Thrombosis
-
Jul 6, 2026, 17:57When Hematocrit Exceeds 70 Percent: Challenges in Peripheral Blood Smear Evaluation and CBC Analysis – Seema Dawood
-
Jul 6, 2026, 17:382026 ACC/AHA Multisociety Dyslipidemia Guideline: Key Updates for Vascular Specialists – Batool Abuhalimeh
-
Jul 6, 2026, 17:27Nicolas Gendron: Should Carbon Footprint Influence Therapeutic Decisions?
-
Jul 6, 2026, 17:15Sanchit Sharma։ Continuous Anticoagulation in PVT with Varices